x

Recent Search Keywords

RIGRANE

RIGRANE

  • Indication
  • Mode of Action
  • Pharmacokinetics
  • Dosage
  • Packing

• Acute treatment of migraine with or without aura in adults.

• Selective 5-HT1B/1D receptor agonist. • Constricts intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides.

• Absorption: Rapidly absorbed, peak plasma concentrations in 1-1.5 hours. • Metabolism: Primarily hepatic via monoamine oxidase-A (MAO-A). • Elimination: Half-life of approximately 2-3 hours, excreted mainly in urine.

• 5-10 mg orally, may repeat after 2 hours if needed, maximum 30 mg/day.

10*4s

Related Product

POLOL